GLP-1 drugs are the next big test
The addition of GIPR co-agonism is what produces Tirzepatides superior metabolic outcomes with the SURPASS-2 trial demonstrating superiority over Semaglutide across both HbA1c reduction and body weight loss, making Tirzepatide the essential research compound for studying what GIPR activation adds to GLP-1R biology
However, a major concern with this approach is the continuity of care and the potential for weight regain upon discontinuation of therapy
This flexibility accommodates various research scenarios while maintaining calculation accuracy
The most frequent observation in FY25 was the failure of a quality control unit to ensure drug products manufactured are in compliance with current good manufacturing practices (cGMP), in accordance with 21 CFR 211.22
Putting these two pieces together, an interest in metabolism and a fundamental capability in human genome science, we learned years ago that polymorphisms or variation in the GIP receptor or its pathway that would lead to its down regulation were protective against obesity and cardiovascular outcomes